<DOC>
	<DOCNO>NCT02317679</DOCNO>
	<brief_summary>Pulsed dye laser ( PDL ) gold standard treatment port-wine stain ( PWS ) . However , outcomes highly variable due new angiogenesis occur laser irradiation . Studies suggest endothelin involved neoangiogenesis occur treatment port-wine stain PDL . The main objective pilot clinical trial evaluate effectiveness safety inhibitor endothelin orally take , Bosentan , follow PDL treatment . Four patient facial port-wine stain resistant PDL treatment include . The treatment Bosentan ( 2 mg/kg twice daily , maximum 62,5 mg twice daily ) give one day PDL irradiation continue 14 day . Only one test area PWS treat PDL . The primary outcome measure important complete improvement ( Investigator Global Assessment 3 4 ) treat area non treat one , 14 day end treatment corresponds one month laser PDL session . The evaluation perform standardized picture 2 independent physician blind region treat .</brief_summary>
	<brief_title>Treatment Resistant Port-wine Stains With Bosentan Pulsed Dye Laser : Pilot Study</brief_title>
	<detailed_description>Pulsed dye laser ( PDL ) gold standard treatment port-wine stain ( PWS ) . However , outcomes highly variable due new angiogenesis occur laser irradiation . Studies suggest endothelin involved neoangiogenesis occur treatment port-wine stain PDL . The main objective pilot clinical trial evaluate effectiveness safety inhibitor endothelin orally take , Bosentan , follow PDL treatment . Four patient facial port-wine stain resistant PDL treatment include . The treatment Bosentan ( 2 mg/kg twice daily , maximum 62,5 mg twice daily ) give one day PDL irradiation ( maximum surface 100 cmÂ² ) continue 14 day . Only one test area PWS treat PDL . The primary outcome measure important complete improvement ( Investigator Global Assessment 3 4 ) treat area non treat one , 14 day end treatment corresponds one month laser PDL session . The evaluation perform standardized picture 2 independent physician blind region treat .</detailed_description>
	<mesh_term>Port-Wine Stain</mesh_term>
	<mesh_term>Hemangioma , Capillary</mesh_term>
	<mesh_term>Vascular Malformations</mesh_term>
	<mesh_term>Bosentan</mesh_term>
	<criteria>Children 7 year old adult age 60 resistant portwine stain treatment PDL include pilot study . The agreement parent child patient alone major require . Subjects register social security . An informed consent sign parent patient suitable age patient alone major . An efficient contraception mandatory patient female age give birth . Exclusion criterion : Hypersensitivity Bosentan one excipients . Mild severe liver disease correspond ChildPugh Score B C. Serum level ASAT and/or ALAT great three time upper limit normal . Concurrent use cyclosporine . Pregnancy .</criteria>
	<gender>All</gender>
	<minimum_age>7 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>December 2014</verification_date>
</DOC>